Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Healthcare Biotechnology
Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Vaxil Bio Ltd > new short position
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(120)
•••
Comment by CamaroZL1on Jan 21, 2021 10:08pm
57 Views
Post# 32356508

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:new short position

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:new short position
bligicka wrote: With 100's of thousands of businesses failing under the pressure of the lockdown the day of reckoning has to be coming .....debt levels have never been higher ....ect its gotta get ugly at some point
CamaroZL1 wrote: Yes those rural properties have been very strong. So many are looking to exit cities these days there are not many rural properties to go around. I dont see a change in that trend anytime soon




Yes I agree...unfortunately but it is what it is. That old saying comes to mind, i owe you a million, im screwed, i owe you 100 million you're screwed. Making think too much these days. I need to get an alternative brokerage acct set up asap. Just incase.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities